Analyst Ratings For Aerie Pharmaceuticals Inc (NASDAQ:AERI)
Today, Mizuho reiterated its Buy rating on Aerie Pharmaceuticals Inc (NASDAQ:AERI) with a price target of $77.00.
There are 9 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Aerie Pharmaceuticals Inc (NASDAQ:AERI) is Buy with a consensus target price of $84.7778 per share, a potential 55.41% upside.
Some recent analyst ratings include
- 11/7/2018-Aerie Pharmaceuticals Inc (NASDAQ:AERI) had its Buy rating reiterated by Mizuho with a $77.00 price target
- 10/2/2018-Aerie Pharmaceuticals Inc (NASDAQ:AERI) had its Buy rating reiterated by Cantor Fitzgerald with a $86.00 price target
- 8/10/2018-Aerie Pharmaceuticals Inc (NASDAQ:AERI) had its Buy rating reiterated by Canaccord Genuity with a $86.00 price target
- On 11/1/2018 Casey C Kopczynski, Insider, sold 11,000 with an average share price of $53.87 per share and the total transaction amounting to $592,570.00.
- On 10/1/2018 Casey C Kopczynski, Insider, sold 11,000 with an average share price of $60.56 per share and the total transaction amounting to $666,160.00.
- On 9/27/2018 Richard J Rubino, CFO, sold 66,605 with an average share price of $60.23 per share and the total transaction amounting to $4,011,619.15.
- On 9/13/2018 Richard J Rubino, CFO, sold 34,512 with an average share price of $60.17 per share and the total transaction amounting to $2,076,587.04.
- On 9/4/2018 Casey C Kopczynski, Insider, sold 11,000 with an average share price of $60.09 per share and the total transaction amounting to $660,990.00.
- On 8/27/2018 Thomas A Mitro, COO, sold 190,000 with an average share price of $60.27 per share and the total transaction amounting to $11,451,300.00.
- On 8/1/2018 Casey C Kopczynski, Insider, sold 11,000 with an average share price of $68.30 per share and the total transaction amounting to $751,300.00.
About Aerie Pharmaceuticals Inc (NASDAQ:AERI)
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Recent Trading Activity for Aerie Pharmaceuticals Inc (NASDAQ:AERI)
Shares of Aerie Pharmaceuticals Inc closed the previous trading session at 54,55 up +1,43 2,69 % with 573800 shares trading hands.